Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Flerie Invest AB
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 25, 2020
Proceeds will be used for advancing the Company's next generation immuno-oncology drug candidates including the clinical development of the Company's lead product, DSP107, an anti-CD47 therapy.